08 Feb Bid farewell to the old year and usher in the new
Being Part of the International Research Community
Looking back at the year 2023, the Chinese Acute Pancreatitis Clinical Trials Group and the Chinese Critical Care Nutrition Trials Group (CAPCTG & CCCNTG) had made great progress in the development of high-quality clinical trials. The past year was the first year when we started to participate in international randomized controlled trials, marking a significant step toward being part of the international research community.
On May 29th, 2023, the kick-off meeting for “The effect of high protein versus usual care on clinical, muscle, physical function and quality of life outcomes in critically ill patients (EFFORT-outcomes)” was successfully carried out. So far, a total of 52 critically ill patients have been screened for trial eligibility, among which 13 patients were finally enrolled in the study and the first patient was randomized on July 7th, 2023.
Through the EFFORT-outcomes trial, CCCNTG deepened cooperation with international researchers from the USA, Australia, and Malaysia. This collaboration helps provide more solid evidence for optimal protein administration in ICU patients.
On June 12th, 2023, Professor Enrique de Madaria, coordinator of the Biliary-Pancreatic Unit at Alicante’s University General Hospital, introduced the WATERLAND trial and shared his perspective on fluid therapy in acute pancreatitis (AP) patients online. The trial was approved by the ethics committee of Jinling Hospital in September. In about 4 months, 43 patients in the early phase of AP were screened and 8 patients were recruited in the study.
In 2024, CAPCTG & CCCNTG will continue to conduct large-scale clinical trials, focusing on standardization, regulation, and internalization. We look forward to having more worldwide collaboration. As the year of the Dragon approaches, CAPCTG & CCCNTG extend our best wishes to each and every one of you!